Cargando...
New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy
INTRODUCTION: The most recently approved antiretroviral, the integrase inhibitor dolutegravir (DTG), is described to be a very potent drug with a unique resistance profile, but a certain degree of cross-resistance to RAL or EVG induced drug resistance, which is mediated mainly by integrase mutations...
Guardado en:
| Publicado en: | J Int AIDS Soc |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
International AIDS Society
2014
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4225390/ https://ncbi.nlm.nih.gov/pubmed/25397494 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7448/IAS.17.4.19749 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|